NCT05883644
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05883644
Title Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (SIERRA)
Acronym SIERRA
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field